Rabbit anti-Human CD263/TRAIL-R3 Monoclonal Antibody for Flow Cytometry - O14798

Core Product Specifications and Parameters

Biological Background: CD263/TRAIL-R3 Function and Localization

• Encodes tumor necrosis factor receptor superfamily member 10C (TNFRSF10C), also known as decoy receptor 1 (DcR1), TRAIL receptor 3 (TRAIL-R3), or lymphocyte inhibitor of TRAIL. It is a GPI-anchored membrane protein that lacks an intracellular death domain.
• Acts as a decoy receptor for the cytotoxic ligand TRAIL (TNFSF10). By competitively binding TRAIL, it inhibits apoptosis induction through functional death receptors TNFRSF10A (DR4) and TNFRSF10B (DR5), thereby protecting cells from TRAIL-induced apoptosis.
• Localized to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, as indicated by its lipoprotein and GPI-anchor keywords.
• Higher expression observed in normal tissues compared to tumor cell lines, with prominent presence in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung, and heart.
• Post-translational modifications include disulfide bond formation and N-linked glycosylation (glycoprotein keyword). The signal peptide is cleaved to yield a mature protein of approximately 27 kDa.
• Member of the TNF receptor superfamily, characterized by cysteine-rich repeats in the extracellular domain.
• Does not contain an intracellular death domain, distinguishing it from pro-apoptotic TRAIL receptors and enabling its role as a negative regulator of TRAIL-mediated apoptosis.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 26-235, which encompasses the extracellular domain of human CD263/TRAIL-R3 (lacking the signal peptide). This design likely generates antibodies recognizing the native cell-surface receptor.
• For flow cytometry (FC), use appropriate cell models expressing human CD263/TRAIL-R3 (e.g., peripheral blood lymphocytes) and include relevant controls to assess specificity, given the potential for binding to other TRAIL receptor family members with similar extracellular domains.
• Fluorescence-conjugated antibodies () allow direct detection without secondary reagents, minimizing background and simplifying multi-color panel design.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with integrated access to high-quality IVD raw materials, covering apoptosis and cancer research targets like CD263/TRAIL-R3. Our portfolio includes validated antibody pairs, optimized monoclonal antibodies, and ancillary reagents for flow cytometry and other applications. We also source rare-target raw materials to accelerate your assay development from concept to clinic.